Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
In Vivo and in Silico Evaluations of a Synthetic Pyrano[3,2-C]Quinoline Derivative As a Potent Anti-Diabetic Agent Publisher



Zare N1 ; Bandarian F2 ; Esfahani EN2 ; Larijani B3 ; Mahdavi M3 ; Mohammadikhanaposhtani M4 ; Najafzadehvarzi H4
Authors

Source: Journal of Diabetes and Metabolic Disorders Published:2023


Abstract

Background: The in vivo assessment of a novel compound is a pivotal step in the development of a new drug. In this study, we selected 1-(2-bromophenyl)-1,11-dihydro-3H-benzo[h]pyrano[3,2-c]quinoline-3,12(2H)-dione (2-BDBPQD), identified as an exemplary α-glucosidase inhibitor in preliminary in vitro assays, for further evaluation in an in vivo anti-diabetic context. Methods: The in vivo anti-diabetic effect of 2-BDBPQD was assessed using a streptozotocin (STZ)-induced diabetic Wistar rat model. Recognizing the relevance of lipid factors in diabetes, we also investigated the impact of this compound on the lipid profile of diabetic Wistar rats. In silico studies, encompassing docking studies and pharmacokinetic predictions of 2-BDBPQD, were conducted. Results: The results obtained indicated a significant reduction in blood glucose levels with 2-BDBPQD treatment compared to acarbose. However, no significant effects on the lipid profile were observed. In silico studies revealed that 2-BDBPQD interacted with key residues in the α-glucosidase active site and exhibited favorable pharmacokinetic properties. Conclusion: In summary, the study demonstrated the in vivo anti-hyperglycemic activity of 2-BDBPQD. Nevertheless, further in vivo evaluations are recommended to comprehensively assess its potential as a new drug for the treatment of diabetes. © 2023, The Author(s), under exclusive licence to Tehran University of Medical Sciences.
Related Docs
View other Related Docs
1. In Vivo Anti-Diabetic and Anti-Lipidemic Evaluations of an Excellent Synthetic Α-Glucosidase Inhibitor With Dihydropyrano[3,2-C]Quinoline Skeleton, Journal of Diabetes and Metabolic Disorders (2024)
2. Alpha-Glucosidase Inhibitory and Hypoglycemic Effects of Imidazole-Bearing Thioquinoline Derivatives With Different Substituents: In Silico, in Vitro, and in Vivo Evaluations, Bioorganic Chemistry (2024)
3. Pyrano[2,3-B]Chromone Derivatives As Novel Dual Inhibitors of Α-Glucosidase and Α-Amylase: Design, Synthesis, Biological Evaluation, and in Silico Studies, Bioorganic Chemistry (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Mahdavi (14)
Mohammad Ali Faramarzi (13)
Other Related Docs
4. Aryl-Quinoline-4-Carbonyl Hydrazone Bearing Different 2-Methoxyphenoxyacetamides As Potent Α-Glucosidase Inhibitors; Molecular Dynamics, Kinetic and Structure–Activity Relationship Studies, Scientific Reports (2024)
5. Quinazolinone-Dihydropyrano[3,2-B]Pyran Hybrids As New Α-Glucosidase Inhibitors: Design, Synthesis, Enzymatic Inhibition, Docking Study and Prediction of Pharmacokinetic, Bioorganic Chemistry (2021)
6. A Review on Synthesis, Mechanism of Action, and Structure-Activity Relationships of 1,2,3-Triazole-Based Α-Glucosidase Inhibitors As Promising Anti-Diabetic Agents, Journal of Molecular Structure (2022)
7. Design, Synthesis, Α-Glucosidase Inhibition and Hypoglycemic Activity of 3-Aceto(Benzo)Hydrazide-1,2,4-Triazines As Potential Anti-Diabetic Agents, European Journal of Medicinal Chemistry Reports (2024)
8. Pyrano[3,2-C]Quinoline Derivatives As New Class of Α-Glucosidase Inhibitors to Treat Type 2 Diabetes: Synthesis, in Vitro Biological Evaluation and Kinetic Study, Medicinal Chemistry (2019)
9. Anti-Diabetic Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Insulin Production, Blood Glucose, and Inflammatory Markers in the Experimental Diabetes Model, Archives of Physiology and Biochemistry (2019)
10. Synthesis, in Vitro Evaluation, and Molecular Docking Studies of Novel Hydrazineylideneindolinone Linked to Phenoxymethyl-1,2,3-Triazole Derivatives As Potential Α-Glucosidase Inhibitors, Bioorganic Chemistry (2021)
11. 1-Phenyl-Β-Carboline-3-Carboxamide-1,2,3-Triazole-N-Phenylacetamide Hybrids As New Α-Glucosidase Inhibitors, Scientific Reports (2025)
12. Substituted Piperazine Conjugated to Quinoline-Thiosemicarbazide As Potent Α-Glucosidase Inhibitors to Target Hyperglycemia, Scientific Reports (2025)
13. Design and Synthesis of Novel Quinoline-Piperazines Fused to a Phenylhydrazinecarbothioamide Scaffold As Promising Α-Glucosidase Inhibitors With Anti-Diabetic Potential, Future Medicinal Chemistry (2025)
14. Design, Synthesis, and in Silico Studies of Quinoline-Based-Benzo[D]Imidazole Bearing Different Acetamide Derivatives As Potent Α-Glucosidase Inhibitors, Scientific Reports (2022)
15. Biological Evaluation of 9-(1H-Indol-3-Yl) Xanthen-4-(9H)-Ones Derivatives As Noncompetitive Α-Glucosidase Inhibitors: Kinetics and Molecular Mechanisms, Structural Chemistry (2019)
16. In Vivo Anti-Hyperglycemic Activity and Toxicity Evaluation of Two Bis-Coumarin Derivative As Potential Α-Glucosidase Inhibitors, Journal of Diabetes and Metabolic Disorders (2025)
17. Diphenyl-Substituted Triazine Derivatives: Synthesis, Α-Glucosidase Inhibitory Activity, Kinetics and in Silico Studies, Future Medicinal Chemistry (2023)
18. Heterocyclic Compounds: Effective Α-Amylase and Α-Glucosidase Inhibitors, Current Topics in Medicinal Chemistry (2017)
19. Synthesis, in Vitro Inhibitor Screening, Structure–Activity Relationship, and Molecular Dynamic Simulation Studies of Novel Thioquinoline Derivatives As Potent Α-Glucosidase Inhibitors, Scientific Reports (2023)
20. Biological Evaluation of New Oxadiazole-Based Synthetic Α-Glycosidase Inhibitors for Hyperglycemia Management: A Research Study, Iranian Journal of Pharmaceutical Sciences (2022)